Share this article on:

Targeted MRI Contrast Agents for Pediatric Hepatobiliary Disease

Courtier, Jesse L.*; Perito, Emily R.; Rhee, Sue; Tsai, Patrika; Heyman, Melvin B.; MacKenzie, John D.*

Journal of Pediatric Gastroenterology & Nutrition: April 2012 - Volume 54 - Issue 4 - p 454–462
doi: 10.1097/MPG.0b013e3182467a4b
Invited Reviews

ABSTRACT: New options are available for the magnetic resonance imaging (MRI) assessment of pediatric hepatobiliary disease. This article describes the potential utility for MRI with contrast agents tailored for hepatobiliary imaging. MRI contrast agents that preferentially target the liver may be helpful in characterizing liver masses and bile duct abnormalities in select children. The imaging approach is noninvasive and relatively rapid to perform. It also provides anatomic and functional information and is a radiation-free alternative to other imaging strategies. This relatively new imaging procedure is placed in the context of more established imaging modalities. The pharmacokinetics, technical considerations, and potential applications of these hepatobiliary-specific contrast agents also are discussed.

*Department of Radiology and Biomedical Imaging

Department of Pediatrics, UCSF Benioff Children's Hospital, San Francisco, CA.

Address correspondence and reprint requests to John D. MacKenzie, MD, Assistant Professor and Chief of Pediatric Radiology, Department of Biomedical Imaging, Pediatric Radiology, UCSF Benioff Children's Hospital, 505 Parnassus Ave, San Francisco, CA 94143-0628 (e-mail:

Received 16 June, 2011

Accepted 12 December, 2011

The present study was supported in part by NIH grants K24 DK060617 (MBH) and T32 DK00762 (ERP).

The authors report no conflicts of interest.

Hepatobiliary-specific contrast agents (HSA) for magnetic resonance imaging (MRI) were recently approved for use in the United States. Originally developed to improve detection and characterization of liver lesions, these agents also provide exquisite detail of bile duct anatomy. HSA are injected intravenously (IV), actively transported into hepatocytes, and excreted into bile ducts. This targeted imaging of the hepatobiliary system is advantageous when characterizing liver lesions and bile duct abnormalities. The test also obtains functional information.

Although originally described in adults (1–4), recent data support several promising pediatric applications for HSA (5,6). MRI with HSA may complement traditional imaging strategies and surmount several difficulties encountered when imaging the pediatric liver and biliary tract. This review describes the present state of the art for imaging the pediatric hepatobiliary system and suggests emerging applications for MRI in light of these new HSA.

Back to Top | Article Outline


Unique challenges exist to noninvasively detect hepatobiliary disorders in the pediatric population. Overall, the ideal imaging test should be noninvasive, rapid to perform, and free of ionizing radiation but still provide exquisite anatomic detail and perhaps functional information. Selection of the appropriate imaging test depends on a number of factors. First, children have smaller anatomic structures and require imaging strategies with higher resolution. For example, normal pediatric common bile duct (CBD) measures between 1 and 3 mm in diameter (7) and intrahepatic bile ducts are submillimeter in size (5), whereas normal adult CBDs approach 6 mm. Second, young children and older children with special needs may be unable to tolerate or hold still for an imaging test, so they may require sedation or anesthesia. Third, the use of imaging tests with ionizing radiation should be minimized given that children may be more sensitive to the long-term affects of radiation exposure than adults.

Back to Top | Article Outline


Ultrasound is the least costly and most widely used noninvasive method to evaluate the pediatric hepatobiliary system. Ultrasound is often the first imaging test of choice because it offers quick, noninvasive evaluation of the liver parenchyma and bile ducts. The sonographic appearance of benign and malignant hepatic neoplasms may be difficult to differentiate by imaging alone, although significant information can be provided. The size and number of hepatic lesions, as well as the appearance of the underling parenchyma, can be readily determined, aiding in narrowing differential diagnoses (8).

CBD dimensions as measured sonographically increase by age and demonstrate small changes in caliber during daily fluctuations in bile flow. In a study of sonographic CBD measurements in 173 healthy patients ages 1 day to 13 years, normal CBD diameters were ≤1.6 mm for patients younger than 1 year and ≤2.5 to 3.0 mm for children and early adolescents (7). Evaluation of the distal CBD by ultrasound can be limited because of overlying bowel gas, and no functional information is obtained.

Back to Top | Article Outline

Computed Tomography

Contrast-enhanced multidetector computed tomography (CT) provides better visualization of the distal CBD than ultrasound. Liver lesions and their involvement with adjacent structures may be depicted with excellent spatial resolution (9). Multiphase contrast-enhanced CT will further characterize liver lesions and improve diagnostic specificity, but at the expense of increased radiation exposure. Dual-phase helical CT is reported to have a sensitivity of 69% to 71% and specificity of 86% to 91% for characterizing benign and malignant hepatic lesions (10). The multiplanar display of CT images also gives improved anatomic localization and visualization of focal liver and biliary lesions. Shorter imaging times also decrease the need for sedation (11,12).

The intrahepatic bile ducts in normal, healthy pediatric patients are often barely perceptible by CT. Their assessment can be augmented with the use of hepatocyte-specific contrast agents such as 52% iodipamide meglumine (Cholografin meglumine; Bracco Diagnostics, Princeton, NJ) (4,5). Use of this agent, however, requires premedication because of its increased risk of allergic reactions as an ionic contrast agent. It is typically used for preoperative assessment of living adult liver transplant donors and is not commonly used in children because of its allergic potential and its use of ionizing radiation. An optimum balance between low-dose radiation and diagnostic quality imaging must be established at institutions performing CT in pediatric patients.

Back to Top | Article Outline

MRI (Conventional)

MRI and magnetic resonance cholangiopancreatography (MRCP) afford comparable anatomic detail to CT without ionizing radiation. MRI is far superior in tissue contrast. Multiphase MRI using nonliver-specific contrast agents has a slightly improved ability to detect liver lesions compared with dual-phase CT but was significantly superior in lesion characterization (13). T1- and T2-weighted appearance and enhancement characteristics assist in narrowing diagnostic considerations in liver lesions. Because MRI is free of ionizing radiation, repeated imaging with multiple phases after the injection of contrast can be obtained. Limitations to MRI include longer imaging times and the need for sedation in younger patients. Improvements with faster sequences will likely lead to further reduction in sedation requirements.

Heavily T2-weighted 3-dimensional (3D)-MRCP sequences also provide exquisitely detailed imaging of the biliary system. T2-weighted MRI images allow creation of maximum intensity projections as well as 3D reconstructed models of the biliary tract. Using this technique, bile ducts as small as 1 mm can be depicted (14). Obtaining such high-resolution duct anatomy requires excellent patient cooperation or anesthesia to limit motion. Moreover, no functional information is provided with the present study.

Back to Top | Article Outline


In cases in which diagnostic confirmation or intervention is necessary, endoscopic retrograde cholangiopancreatography (ERCP) and percutaneous transhepatic cholangiography may be performed. These tests involve the direct injection of contrast into the biliary system and allow for both diagnosis and intervention. The risks of this procedure that appear to have similar rates in adults and children (15,16) must be balanced with the higher resolution and therapeutic options offered by ERCP over MRI with HSA.

Back to Top | Article Outline


MRI contrast agents for hepatobiliary imaging are injected IV and specifically target the liver. Both HSA and more routinely used non-HSA are designed with 2 basic components: gadolinium and a chelate for gadolinium. Gadolinium alters surrounding water hydrogen molecules, producing increased signal intensity on T1-weighted MR images.

The chelate prevents the escape of free gadolinium, and, more important, the outer coat of the chelate localizes the HSA to the liver. The outer surface of the chelate is recognized by hepatocytes for active transport into the liver and subsequent biliary excretion. Several transport mechanisms exist that allow transport from the hepatocytes to the biliary system. HSA are low in molecular weight, so they will pass readily into interstitial spaces; contrast remaining in the blood pool will be excreted rapidly by the kidneys.

Several contrast agents have been tested for depiction of the biliary system. Gadoxetate disodium was Food and Drug Administration–approved for use in the United States in 2008 and marketed as Eovist in the United States and Primovist in Europe (17,18). Although imaging children with gadoxetate is presently an off-label use, an ongoing, multicenter observational cohort study sponsored by the manufacturer is under way to examine the safety and efficacy of gadoxetate in pediatric patients (

HSA initially follow similar blood distribution kinetics as other non-HSA. Peak arterial enhancement typically occurs within 30 seconds and peak portal venous enhancement within 60 seconds. Peak enhancement varies depending on cardiac output and age of the child. Obtaining imaging during this early time will produce images similar to a routine contrast-enhanced abdominal MRI (non-HSA), yielding excellent depictions of abdominal organs and masses.

Later than 60 seconds after the IV injection, the HSA show a different biodistribution than non-HSA. The liver takes up approximately 50% of the HSA, with a noticeable decrease in hepatic venous enhancement and increase in liver enhancement (Fig. 1). Approximately 50% of HSA contrast is excreted through the kidneys, compared with the majority of non-HSA contrast.

During the next 20 to 40 minutes, the hepatocytes transport and excrete the HSA into the bile ducts. This accumulation of contrast material facilitates depiction of the biliary system (19). Maximal biliary excretion, and thus optimal visualization of duct anatomy, occurs at approximately 20 to 60 minutes.

Because HSA relies on hepatocyte transport mechanisms, alterations in liver function alter the transport of HSA. Thus, liver function must be considered when interpreting these MRI examinations (20). Patients with end-stage or decompensated cirrhosis will have substantially decreased liver uptake and biliary excretion, so liver lesions and bile ducts will be less well visualized in a cirrhotic liver (21). This is likely the result of reduced number and function of organic anion transporting polypeptide 1 and canalicular multispecific organic anion transporter. Unfortunately, decreased liver uptake and excretion of HSA do not appear to correlate with serum markers of liver function (22).

Several other facets need to be considered when interpreting MRI with HSA in patients with liver dysfunction. Uptake and excretion times are similar to normal in patients with early or well-compensated cirrhosis (20). Alterations in the kinetics of HSA biodistribution in various forms of pediatric liver dysfunction have not been studied to date, but a safe assumption is that uptake is delayed. Cholestasis and cirrhosis are also associated with a longer plasma half-life but attenuated enhancement of the hepatic and portal veins. Renal insufficiency will further prolong blood vessel enhancement. As with non-HSA, HSA are contraindicated in patients with decreased glomerular filtration rates because of the associations among renal failure, IV gadolinium administration, and nephrogenic systemic fibrosis.

Back to Top | Article Outline


Imaging of the hepatobiliary system has rapidly advanced during the past 5 to 6 years. High-resolution images of the biliary tree can now be routinely obtained in 20 to 30 seconds, well within the ability of most children to hold their breath. New hardware and pulse sequence design have enabled faster imaging with good signal-to-noise ratio (SNR).

High SNR is important to produce quality images with adequate image resolution and tissue contrast. These capabilities are found on MRI equipment developed by the major MRI manufacturers within the last 5 to 6 years. Increased field strength (23–25), fast gradients, and multichannel array coils (26–28) give increased performance with higher SNR, better spatial resolution, and improved speed. This combination greatly improves body imaging, and high-resolution images can be obtained in a single breath-hold.

The other critical component in both conventional MRI and MRI with HSA is the selection of pulse sequences. Pulse sequences drive MRI hardware to create images that emphasize different tissues based on T1 and T2 weighting. Pulse sequence design also allows wide flexibility in balancing image resolution and acquisition speed.

The strategy for imaging bile ducts with HSA is completely different from conventional MRCP. Conventional MRI/MRCP emphasizes structures that contain primarily water and uses heavily T2-weighted pulse sequences. Tissue contrast is decreased on T2-weighted imaging, such that structures containing water—like the lumens of the bile ducts, gallbladder, duodenum, and renal collecting system—are bright in signal intensity. Surrounding tissues that contain little water produce little signal, so the bile ducts stand out in contrast and are well depicted.

In MRI with HSA, 2 factors allow for increased visualization of ductal anatomy. First, rather than highlighting water contained in ducts, the T1-weighted pulse sequences highlight structures with gadolinium. Gadolinium increases the SNR for better visualization of duct anatomy (4,29). Second, the 3D gradient echo T1-weighted imaging is performed in a single breath-hold, at a higher resolution, and can be transformed into 3D images (23). Ductal anatomy may be visualized in 1-mm slice thickness (Fig. 2). This resolution is less than percutaneous or endoscopic cholangiography but MRCP provides extraluminal information, is less invasive, and is radiation free.

One important drawback of MRI with HSA should be mentioned. The time spent waiting for excretion of the contrast agent into the biliary system results in longer overall imaging times than conventional T2-weighted MRCP. Although the extra 20 to 45 minutes the child spends in the MRI scanner are approximately 30% to 100% longer than conventional MRCP, select children will likely benefit from the present study as illustrated by the cases below.

Back to Top | Article Outline


Liver Lesions

Several clinical scenarios exist in which HSA provides information beyond other tests for the diagnosis and management of liver masses. Although liver masses are rare in children, proper classification is crucial for appropriate management. HSA identifies and helps distinguish between benign and malignant lesions and extends the capabilities of diagnostic imaging beyond other imaging modalities (CT/ultrasound/conventional MRI). Table 1 lists lesions in which HSA may be useful to characterize liver lesions in children.

Back to Top | Article Outline

Focal Nodular Hyperplasia

MRI with HSA is an excellent diagnostic choice for characterizing focal nodular hyperplasia (FNH). The unique cellular composition of FNH, combined with the hepatocyte and biliary targeting properties of HSA, usually allow separation of FNH from other liver lesions on MRI. FNH contains normal hepatocytes, which readily take up HSA. Because of the malformed bile ducts present in FNH the hepatocytes fail to excrete the HSA. Thus, FNH lesions readily enhance on the arterial phase of imaging and continue to enhance for an extended period (Fig. 3).

FNH lesions remain high in signal intensity on MRI long after other liver lesions have washed out (lost signal intensity from clearance of the HSA) compared with surrounding normal liver parenchyma (Fig. 3C). Separating FNH from metastasis and malignant tumors of liver origin is one of the primary advantages of HSA over ultrasound and conventional CT and MRI. Several studies have shown improved diagnostic capabilities for detecting FNH during the liver-specific phase of gadoxetate compared with noncontrast MR and spiral CT (30–32).

Back to Top | Article Outline

Hepatic Adenoma

Similar to FNH, hepatic adenomas contain hepatocytes, although adenomas do not contain bile ducts. Adenomas are typically hyperintense to liver parenchyma on T1-weighted imaging (either secondary to intratumoral fat and/or hemorrhage), enhance on arterial phase imaging, and commonly show loss of signal on opposed phase sequences. Fat content is not specific for adenoma, however, because hepatocellular carcinoma (HCC) can also contain fat (33). Adenomas also tend to be solitary, round, or ovoid, contain a capsule, and often lack the central scar of FNH. Hepatic adenomas are rare in the pediatric population but are seen occasionally in adolescent girls, particularly those on oral contraceptives, or in children with glycogen storage disease type 1a, and in patients with Fanconi anemia (34).

Experience with other hepatocyte-specific agents, specifically gadobenate dimeglumine, suggests that the lack of bile ducts can be used to distinguish between adenomas and FNH. Adenomas are typically hypointense to liver parenchyma on hepatocyte phase imaging because of their lack of biliary canaliculi (35). FNH, as described previously, often demonstrates hyperenhancement on hepatocyte phase imaging. There is, however, reported variability in the enhancement pattern of adenomas with gadoxetate and larger dedicated investigations are needed (20). Because the risk of hemorrhage, rupture, and malignant transformation associated with adenomas makes surgical resection the usual treatment, correct diagnosis is important and often possible with HSA.

Back to Top | Article Outline

Primary Malignant Liver Lesions

Hepatoblastoma, HCC, and liver sarcomas are the primary malignant liver tumors in children and imaging may help distinguish these tumors from benign masses. Features atypical for FNH or hepatic adenoma on MRI with HSA should raise suspicion for a malignant tumor.

Hepatoblastoma is the most common primary malignant liver neoplasm in pediatric patients, with the vast majority (>90%) of patients younger than 5 years at presentation (36). An association exists between hepatoblastoma and certain syndromes, most notably Beckwith-Weideman. The majority (>80%) appear as large solitary lesions. These tumors contain differing amounts of epithelial and mesenchymal elements and thus can have a variable imaging appearance. Typical imaging appearance includes heterogeneous T2 hyperintensity, predominant T1 hypointensity, and heterogeneous enhancement with standard MRI contrast agents. With hepatobiliary-specific agents, hepatoblastoma has been described as hypointense to background liver parenchyma on all of the phases (37).

HCC contains hepatocytes dedifferentiated to varying degrees, and HCC tends to show rapid arterial enhancement just as FNH; however, unlike FNH, HCC lesions will quickly wash out and not show delayed enhancement (Figs. 4 and 5). This washout of HSA should raise the possibility that a lesion is HCC.

Several caveats are important in interpreting imaging studies when HCC is suspected. HCC can be difficult to differentiate from regenerative nodules in the cirrhotic liver (Fig. 5). Regenerative nodules contain functioning hepatocytes surrounded by fibrous septa. Thus, uptake of HSA in the hepatocyte phase should ideally match that of background liver tissue (21). There is, however, a spectrum of appearance in regenerative nodules that can be complicated further by underlying heterogeneous enhancement in a cirrhotic liver. Studies in adults suggest that HSA may be particularly useful in differentiating small HCC lesions from other hypervascular arterial enhancing pseudolesions because the former are usually hypointense in the hepatobiliary phase and the latter are typically isointense (38). The appearance of HCC on hepatocyte phase imaging depends on the degree of differentiation (20). Moderate to poorly differentiated HCC appear hypointense relative to background liver parenchyma during the hepatocyte phase because they do not uptake HSA well, but well-differentiated HCC with functioning hepatocytes can mimic the uptake of benign tumors.

Back to Top | Article Outline

Liver Lesions With No Clearly Established Role for Hepatobiliary-specific Agents

HSA would not be expected to provide additional information for liver lesions that lack hepatocytes (Table 1). For example, hepatoblastomas contain mainly incompletely differentiated hepatoblasts and mesenchymal cells (34). Given the cellular constituents of this tumor, HSA is not likely to add significantly to standard contrast-enhanced MRI in its diagnosis because this lesion will likely have isointense signal intensity to background imaging on hepatocyte phase imaging.

Infection is usually readily separated from tumor on conventional imaging. MRI with HSA will provide similar information as non-HSA. Central enhancement is usually not seen in infection because the lesions in focal liver infections tend to displace or replace hepatocytes. The lack of early or delayed enhancement of a liver lesion raises the possibility of infection.

Similarly, liver cysts are usually readily appreciated on conventional imaging. Liver hemangiomas are also characterized well by ultrasound and confirmed by multiphase MRI with non-HSA (Fig. 6). Table 2 summarizes the imaging appearance of the commonly encountered pediatric liver lesions with HSA.

Back to Top | Article Outline

Biliary Duct Pathology

MRCP with HSA can add additional information to the diagnosis and characterization of pediatric bile duct abnormalities. Several studies illustrate the utility of MRCP for defining bile duct abnormalities and pinpointing diagnosis in children (39–41). MRCP with HSA will likely expand these capabilities. Furthermore, our initial experience with HSA suggests that this imaging tool is particularly useful in subtle or atypical biliary lesions, as illustrated in the cases below.

Back to Top | Article Outline

Intrinsic Bile Duct Obstruction

MRCP with HSA has several roles when evaluating children with known or suspected biliary stone disease. First, MRI with HSA provides radiation-free evaluation of the intraluminal anatomy with exquisite resolution (Fig. 7). Second, unlike ultrasound, in which bowel gas may obscure the distal CBD, MRCP with HSA can depict the majority of the biliary system and is less invasive than ERCP.

Although MRCP with HSA is usually not the first imaging test to consider when doing a workup children for bile duct stones, moving to MRCP with HSA may be reasonable if ultrasound is uninformative. Furthermore, MRI may reveal unexpected findings outside the ducts. This may be helpful in patients with underlying chronic diseases who are susceptible to biliary stones as well as other abdominal pathologies, such as chronic hemolytic disease, cystic fibrosis, history of total parenteral nutrition or intestinal resection, familial hyperlipidemias, and cirrhosis or chronic cholestasis (42). The utility of HSA is expected to increase because of the anticipated increase in prevalence of biliary obstruction in tandem with the obesity epidemic in the United States (43).

Back to Top | Article Outline

Extrinsic Bile Duct Obstruction

The capability of MRCP with HSA to show extraluminal pathology also helps with the diagnosis of extraluminal bile duct stenosis. Extraluminal pathologies such as tumor are readily depicted on the abdominal imaging component of the examination and help distinguish between bile duct stenosis (Fig. 7) and extrinsic compression from masses.

Back to Top | Article Outline

Aberrant and Congenital Variations in Bile Duct Anatomy

MRI with HSA may have a role in mapping out the anatomy of choledochal cysts. Although cysts are seen readily on conventional MRI (44), MRI with HSA can be particularly helpful in diagnosing extremely subtle dilatations or stenosis of the biliary or pancreatic ducts or show communication between pancreatic and biliary systems (Fig. 8). This may assist in surgical planning.

Back to Top | Article Outline

Subtle Abnormalities of the Ducts: Primary Sclerosing Cholangitis

The high-resolution imaging provided by MRCP with HSA may show subtle lesions in early primary sclerosing cholangitis (PSC). The onset of PSC is usually insidious, with vague signs and symptoms (45). Thus, diagnosis usually requires clinical suspicion and targeted imaging. Both MRCP and ERCP are helpful in diagnosis, with sensitivities estimated at 80% to 91% and specificities of 80% to 96% in blinded studies of adult patients (46,47). Studies in a pediatric-specific population revealed sensitivity of 81%, specificity of 100%, negative predictive value of 62%, positive predictive value of 100%, and accuracy of 85% in the diagnosis of PSC in children (48). Our experience suggests that the biliary excretion of HSA aids in the noninvasive identification of subtle PSC changes, particularly in the intrahepatic ducts.

Back to Top | Article Outline


The cases above illustrate applications specifically relevant for children with hepatobiliary disease and suggest the potential of HSA for additional diagnostic purposes. Given the recent Food and Drug Administration approval of gadoxetate disodium for adults, its use in children has been guided by early experience with adults. The indications in childhood hepatobiliary disease rely on this adult experience. Specific roles for MRI with HSA are presently undertested in children.

The excretion of gadoxetate disodium through the biliary ductal system also may be useful in delineating bile duct patency or perforations. One case report suggests that HSA can detect active bile leak following laparoscopic cholecystectomy (49). Bile duct injury and leaks occur in children after liver transplantation and choledochal cyst resections as well as more routine operations such as cholecystectomy. HSA may provide a noninvasive method to delineate the extent and location of bile leaks; however, MRI does require sedation in younger children and does not provide therapeutic opportunities, as does ERCP or percutaneous transhepatic cholangiography. Use in the peritransplant period should also be carefully considered depending on the patient's present and past renal function, given the risk for nephrogenic systemic sclerosis.

Although a role for HSA in children suspected of having biliary atresia has been proposed, the potential duct and liver dysfunction in these patients will likely alter the biliary excretion of HSA. Similar to hepatobiliary iminodiacetic acid scans, poor uptake and excretion prolongs imaging times and delivers less HSA into the liver and ducts, making it challenging to differentiate biliary atresia, Alagille syndrome, or neonatal hepatitis by using MRI with HSA. Liver uptake and excretion of HSA will be delayed, decreased, or absent within a reasonable time frame for imaging in all 3 of these entities.

The small size of bile ducts in neonates and infants coupled with decreased biliary excretion will make visualization of ducts, when present, challenging given the present resolution and tissue contrast capabilities of MRI with HSA. More important, as with hepatobiliary iminodiacetic acid scans, lack of visualization of the ducts does not rule in biliary atresia, so MRCP with HSA would not avoid the need for intraoperative cholangiogram or liver biopsy in suspected biliary atresia. Despite these limitations, criteria and a role for MRCP with HSA may be developed to triage neonates suspected of having biliary atresia, especially when function tests are still relatively normal.

MRI with HSA also may be useful for identifying and delineating postoperative remnants of choledochal cysts. Cholangiocarcinoma is rare in children, but it is a major risk of retained choledochal cysts. It is also seen in children with sclerosing cholangitis and familial adenomatous polyposis. Preliminary studies in adults suggest that MRI with HSA may improve cholangiocarcinoma detection because the abnormal epithelium shows irregular peripheral rim enhancement during the arterial phase followed by hypointensity relative to adjacent liver in the hepatocyte phase (20).

Back to Top | Article Outline


MRI contrast agents targeted to the liver and bile ducts add a new dimension for diagnosis and patient management and will likely complement existing imaging techniques. Interpretation of MRI with HSA uses the unique properties of the contrast agent for uptake into liver cells and subsequent excretion into the biliary system. These properties give functional information about liver masses and provide exquisite anatomic detail of the bile ducts. Although additional experience will be necessary to further establish roles for pediatric patients suspected of having liver lesions or bile duct disorders, MRI with HSA will likely play an increasing role in clinical decision making.

Back to Top | Article Outline


1. Gupta RT, Brady CM, Lotz J, et al. Dynamic MR imaging of the biliary system using hepatocyte-specific contrast agents. AJR Am J Roentgenol 2010; 195:405–413.
2. Lee NK, Kim S, Lee JW, et al. Biliary MR imaging with Gd-EOB-DTPA and its clinical applications. Radiographics 2009; 29:1707–1724.
3. Seale MK, Catalano OA, Saini S, et al. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics 2009; 29:1725–1748.
4. Yeh BM, Liu PS, Soto JA, et al. MR imaging and CT of the biliary tract. Radiographics 2009; 29:1669–1688.
5. Emery KH. Cross-sectional imaging of pediatric biliary disorders. Pediatr Radiol 2010; 40:438–441.
6. Tamrazi A, Vasanawala SS. Functional hepatobiliary MR imaging in children. Pediatr Radiol 2011;41:1250–8.
7. Hernanz-Schulman M, Ambrosino MM, Freeman PC, et al. Common bile duct in children: sonographic dimensions. Radiology 1995; 195:193–195.
8. Varich L. Ultrasound of pediatric liver masses. Ultrasound Clin 2010; 4:137–152.
9. Yekeler E. Pediatric abdominal applications of multidetector-row CT. Eur J Radiol 2004; 52:31–43.
10. Kamel IR, Choti MA, Horton KM, et al. Surgically staged focal liver lesions: accuracy and reproducibility of dual-phase helical CT for detection and characterization. Radiology 2003; 227:752–757.
11. Pappas JN, Donnelly LF, Frush DP. Reduced frequency of sedation of young children with multisection helical CT. Radiology 2000; 215:897–899.
12. White KS. Reduced need for sedation in patients undergoing helical CT of the chest and abdomen. Pediatr Radiol 1995; 25:344–346.
13. Semelka RC, Martin DR, Balci C, et al. Focal liver lesions: comparison of dual-phase CT and multisequence multiplanar MR imaging including dynamic gadolinium enhancement. J Magn Reson Imaging 2001; 13:397–401.
14. Zhang J, Israel GM, Hecht EM, et al. Isotropic 3D T2-weighted MR cholangiopancreatography with parallel imaging: feasibility study. AJR Am J Roentgenol 2006; 187:1564–1570.
15. Hekimoglu K, Ustundag Y, Dusak A, et al. MRCP vs. ERCP in the evaluation of biliary pathologies: review of current literature. J Dig Dis 2008; 9:162–169.
16. Varadarajulu S, Wilcox CM, Hawes RH, et al. Technical outcomes and complications of ERCP in children. Gastrointest Endosc 2004; 60:367–371.
17. Food and Drug Administration. Drug approval package. Eovist (gadoxetate disodium) injection. Accessed April 15, 2011.
18. Food and Drug Administration. Eovist full prescribing information. Accessed April 15, 2011.
19. Vogl TJ, Kummel S, Hammerstingl R, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996; 200:59–67.
20. Ringe KI, Husarik DB, Sirlin CB, et al. Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol 2010; 195:13–28.
21. Cruite I, Schroeder M, Merkle EM, et al. Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver. AJR Am J Roentgenol 2010; 195:29–41.
22. Motosugi U, Ichikawa T, Sou H, et al. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging 2009; 30:1042–1046.
23. MacKenzie JD, Vasanawala SS. Advances in pediatric MR imaging. Magn Reson Imaging Clin N Am 2008; 16:385–402.
24. de Bazelaire CM, Duhamel GD, Rofsky NM, et al. MR imaging relaxation times of abdominal and pelvic tissues measured in vivo at 3.0 T: preliminary results. Radiology 2004; 230:652–659.
25. Edelstein WA, Glover GH, Hardy CJ, et al. The intrinsic signal-to-noise ratio in NMR imaging. Magn Reson Med 1986; 3:604–618.
26. Pruessmann KP, Weiger M, Scheidegger MB, et al. SENSE: sensitivity encoding for fast MRI. Magn Reson Med 1999; 42:952–962.
27. Shellock FG. Radiofrequency energy-induced heating during MR procedures: a review. J Magn Reson Imaging 2000; 12:30–36.
28. Sodickson DK, Manning WJ. Simultaneous acquisition of spatial harmonics (SMASH): fast imaging with radiofrequency coil arrays. Magn Reson Med 1997; 38:591–603.
29. Paolantonio P, Ferrari R, Vecchietti F, et al. Current status of MR imaging in the evaluation of IBD in a pediatric population of patients. Eur J Radiol 2009; 69:418–424.
30. Zech CJ, Grazioli L, Breuer J, et al. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol 2008; 43:504–511.
31. Hammerstingl R, Huppertz A, Breuer J, et al. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol 2008; 18:457–467.
32. Raman SS, Leary C, Bluemke DA, et al. Improved characterization of focal liver lesions with liver-specific gadoxetic acid disodium-enhanced magnetic resonance imaging: a multicenter phase 3 clinical trial. J Comput Assist Tomogr 2010; 34:163–172.
33. Chung EM, Cube R, Lewis RB, et al. From the archives of the AFIP: Pediatric liver masses: radiologic-pathologic correlation, part 1. Benign tumors. Radiographics 2010; 30:801–826.
34. Finegold MJ, Egler RA, Goss JA, et al. Liver tumors: pediatric population. Liver Transpl 2008; 14:1545–1556.
35. Grazioli L, Morana G, Kirchin MA, et al. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 2005; 236:166–177.
36. Chung EM, Lattin GE Jr, Cube R, et al. From the archives of the AFIP: pediatric liver masses: radiologic-pathologic correlation, part 2. Malignant tumors. Radiographics 2011; 31:483–507.
37. Meyers AB, Towbin AJ, Serai S, et al. Characterization of pediatric liver lesions with gadoxetate disodium. Pediatr Radiol 2011; 41:1183–1197.
38. Sun HY, Lee JM, Shin CI, et al. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol 2010; 45:96–103.
39. Chavhan GB, Roberts E, Moineddin R, et al. Primary sclerosing cholangitis in children: utility of magnetic resonance cholangiopancreatography. Pediatr Radiol 2008; 38:868–873.
40. Krause D, Cercueil JP, Dranssart M, et al. MRI for evaluating congenital bile duct abnormalities. J Comput Assist Tomogr 2002; 26:541–552.
41. Takaya J, Nakano S, Imai Y, et al. Usefulness of magnetic resonance cholangiopancreatography in biliary structures in infants: a four-case report. Eur J Pediatr 2007; 166:211–214.
42. Heubi JE. Diseases of the gallbladder in infancy, childhood, and adolescence. In: Suchy FJ, Sokol RJ, Balistreri WF, eds. Liver Disease in Children. Cambridge, UK: Cambridge University Press; 2007: 346–66.
43. Wang G, Dietz WH. Economic burden of obesity in youths aged 6 to 17 years: 1979–1999. Pediatrics 2002;109:E81–1.
44. Delaney L, Applegate KE, Karmazyn B, et al. MR cholangiopancreatography in children: feasibility, safety, and initial experience. Pediatr Radiol 2008; 38:64–75.
45. Erickson NI, Balistreri WF. Sclerosing cholangitis. In: Suchy FJ, Sokol RJ, Balistreri WF, eds. Liver Disease in Children. Cambridge, UK: Cambridge University Press; 2007: 459–77.
46. Berstad AE, Aabakken L, Smith HJ, et al. Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2006; 4:514–520.
47. Moff SL, Kamel IR, Eustace J, et al. Diagnosis of primary sclerosing cholangitis: a blinded comparative study using magnetic resonance cholangiography and endoscopic retrograde cholangiography. Gastrointest Endosc 2006; 64:219–223.
48. Ferrara C, Valeri G, Salvolini L, et al. Magnetic resonance cholangiopancreatography in primary sclerosing cholangitis in children. Pediatr Radiol 2002; 32:413–417.
49. Marin D, Bova V, Agnello F, et al. Gadoxetate disodium-enhanced magnetic resonance cholangiography for the noninvasive detection of an active bile duct leak after laparoscopic cholecystectomy. J Comput Assist Tomogr 2010; 34:213–216.

contrast agent; liver and biliary disease; magnetic resonance imaging

Copyright 2012 by ESPGHAN and NASPGHAN